|
|
Chimeric antigen receptor T cell therapies for acute myeloid leukemia |
Bin Gu, Jianhong Chu, Depei Wu() |
Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology of Soochow University, Suzhou Institute of Blood and Marrow Transplantation, Suzhou 215006, China |
|
|
Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies. Relapse remains the main cause of treatment failure, especially for patients with intermediate or high risk stratification. Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect, which unfortunately puts the patient at risk of serious complications, such as graft-versus-host disease. Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease. In this review, we focus on the most recent and promising advances in CAR T therapies for AML.
|
Keywords
acute myeloid leukemia
CAR T
immunotherapy
|
Corresponding Author(s):
Depei Wu
|
Just Accepted Date: 29 September 2020
Online First Date: 11 January 2021
Issue Date: 24 December 2020
|
|
1 |
H Döhner, DJ Weisdorf, CD Bloomfield. Acute myeloid leukemia. N Engl J Med 2015; 373(12): 1136–1152
https://doi.org/10.1056/NEJMra1406184
pmid: 26376137
|
2 |
FR Appelbaum, H Gundacker, DR Head, ML Slovak, CL Willman, JE Godwin, JE Anderson, SH Petersdorf. Age and acute myeloid leukemia. Blood 2006; 107(9): 3481–3485
https://doi.org/10.1182/blood-2005-09-3724
pmid: 16455952
|
3 |
K Mrózek, G Marcucci, D Nicolet, KS Maharry, H Becker, SP Whitman, KH Metzeler, S Schwind, YZ Wu, J Kohlschmidt, MJ Pettenati, NA Heerema, AW Block, SR Patil, MR Baer, JE Kolitz, JO Moore, AJ Carroll, RM Stone, RA Larson, CD Bloomfield. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30(36): 4515–4523
https://doi.org/10.1200/JCO.2012.43.4738
pmid: 22987078
|
4 |
C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, H Bodenstein, HJ Tischler, R Stuhlmann, U Schuler, F Stölzel, M von Bonin, H Wandt, K Schäfer-Eckart, M Schaich, G Ehninger. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29(20): 2758–2765
https://doi.org/10.1200/JCO.2010.32.8500
pmid: 21632498
|
5 |
JC Byrd, K Mrózek, RK Dodge, AJ Carroll, CG Edwards, DC Arthur, MJ Pettenati, SR Patil, KW Rao, MS Watson, PR Koduru, JO Moore, RM Stone, RJ Mayer, EJ Feldman, FR Davey, CA Schiffer, RA Larson, CD Bloomfield; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100(13): 4325–4336
https://doi.org/10.1182/blood-2002-03-0772
pmid: 12393746
|
6 |
JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhäuser, G Juliusson, Z Råcil, JM Rowe, N Russell, M Mohty, B Löwenberg, G Socié, D Niederwieser, GJ Ossenkoppele. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9(10): 579–590
https://doi.org/10.1038/nrclinonc.2012.150
pmid: 22949046
|
7 |
MV Maus, SA Grupp, DL Porter, CH June. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123(17): 2625–2635
https://doi.org/10.1182/blood-2013-11-492231
pmid: 24578504
|
8 |
J Wei, X Han, J Bo, W Han. Target selection for CAR-T therapy. J Hematol Oncol 2019; 12(1): 62
https://doi.org/10.1186/s13045-019-0758-x
pmid: 31221182
|
9 |
E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ACM Martens, S Zweegman, N van de Donk, RWJ Groen, HM Lokhorst, T Mutis. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther 2017; 25(8): 1946–1958
https://doi.org/DOI: 10.1016/j.ymthe.2017.04.024
pmid: 28506593
|
10 |
AJ Walker, RG Majzner, L Zhang, K Wanhainen, AH Long, SM Nguyen, P Lopomo, M Vigny, TJ Fry, RJ Orentas, CL Mackall. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther 2017; 25(9): 2189–2201
https://doi.org/DOI: 10.1016/j.ymthe.2017.06.008
pmid: 28676342
|
11 |
DL Porter, BL Levine, M Kalos, A Bagg, CH June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365(8): 725–733
https://doi.org/10.1056/NEJMoa1103849
pmid: 21830940
|
12 |
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, DT Teachey, A Chew, B Hauck, JF Wright, MC Milone, BL Levine, CH June. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368(16): 1509–1518
https://doi.org/10.1056/NEJMoa1215134
pmid: 23527958
|
13 |
F Ceppi, RA Gardner. Chimeric antigen receptor T cells for B-cell acute lymphoblastic leukemia. Cancer J 2019; 25(3): 191–198
https://doi.org/10.1097/PPO.0000000000000375
pmid: 31135526
|
14 |
E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ND Roberts, NE Potter, M Heuser, F Thol, N Bolli, G Gundem, P Van Loo, I Martincorena, P Ganly, L Mudie, S McLaren, S O’Meara, K Raine, DR Jones, JW Teague, AP Butler, MF Greaves, A Ganser, K Döhner, RF Schlenk, H Döhner, PJ Campbell. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016; 374(23): 2209–2221
https://doi.org/10.1056/NEJMoa1516192
pmid: 27276561
|
15 |
E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, R Sussman, C Lanauze, M Ruella, MR Gazzara, NM Martinez, CT Harrington, EY Chung, J Perazzelli, TJ Hofmann, SL Maude, P Raman, A Barrera, S Gill, SF Lacey, JJ Melenhorst, D Allman, E Jacoby, T Fry, C Mackall, Y Barash, KW Lynch, JM Maris, SA Grupp, A Thomas-Tikhonenko. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015; 5(12): 1282–1295
https://doi.org/10.1158/2159-8290.CD-15-1020
pmid: 26516065
|
16 |
R Gardner, D Wu, S Cherian, M Fang, LA Hanafi, O Finney, H Smithers, MC Jensen, SR Riddell, DG Maloney, CJ Turtle. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 2016; 127(20): 2406–2410
https://doi.org/10.1182/blood-2015-08-665547
pmid: 26907630
|
17 |
E Jacoby, SM Nguyen, TJ Fountaine, K Welp, B Gryder, H Qin, Y Yang, CD Chien, AE Seif, H Lei, YK Song, J Khan, DW Lee, CL Mackall, RA Gardner, MC Jensen, JF Shern, TJ Fry. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 2016; 7(12320): 12320
https://doi.org/10.1038/ncomms12320
pmid: 27460500
|
18 |
M Sadelain. Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol 2016; 41: 68–76
https://doi.org/10.1016/j.coi.2016.06.004
pmid: 27372731
|
19 |
H Yu, E Sotillo, C Harrington, G Wertheim, M Paessler, SL Maude, SR Rheingold, SA Grupp, A Thomas-Tikhonenko, V Pillai. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol 2017; 92(1): E11–E13
https://doi.org/10.1002/ajh.24594
pmid: 27779774
|
20 |
DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai, K Tainton, K Chen, M Shin, DM Wall, D Honemann, P Gambell, DA Westerman, J Haurat, JA Westwood, AM Scott, L Kravets, M Dickinson, JA Trapani, MJ Smyth, PK Darcy, MH Kershaw, HM Prince. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21(11): 2122–2129
https://doi.org/DOI: 10.1038/mt.2013.154
pmid: 23831595
|
21 |
F Perna, SH Berman, RK Soni, J Mansilla-Soto, J Eyquem, M Hamieh, RC Hendrickson, CW Brennan, M Sadelain. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 2017; 32(4): 506–519.e5
https://doi.org/10.1016/j.ccell.2017.09.004
pmid: 29017060
|
22 |
FJ Giles, HM Kantarjian, SM Kornblau, DA Thomas, G Garcia-Manero, TA Waddelow, CL David, AT Phan, DE Colburn, A Rashid, EH Estey. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92(2): 406–413
https://doi.org/10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U
pmid: 11466696
|
23 |
SS Kenderian, M Ruella, O Shestova, M Klichinsky, V Aikawa, JJ Morrissette, J Scholler, D Song, DL Porter, M Carroll, CH June, S Gill. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 2015; 29(8): 1637–1647
https://doi.org/10.1038/leu.2015.52
pmid: 25721896
|
24 |
C O’Hear, JF Heiber, I Schubert, G Fey, TL Geiger. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica 2015; 100(3): 336–344
https://doi.org/10.3324/haematol.2014.112748
pmid: 25480499
|
25 |
S Rafiq, TJ Purdon, LM Schultz, RJ Brentjens. CD33-directed chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemia (AML). Blood 2016; 128(22): 2825
https://doi.org/10.1182/blood.V128.22.2825.2825
|
26 |
QS Wang, Y Wang, HY Lv, QW Han, H Fan, B Guo, LL Wang, WD Han. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 2015; 23(1): 184–191
https://doi.org/DOI: 10.1038/mt.2014.164
pmid: 25174587
|
27 |
MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, D Schreeder, M Klichinsky, O Shestova, MS Kozlowski, KD Cummins, X Shan, M Shestov, A Bagg, JJD Morrissette, P Sekhri, CR Lazzarotto, KR Calvo, DB Kuhns, RE Donahue, GK Behbehani, SQ Tsai, CE Dunbar, S Gill. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 2018; 173(6): 1439–1453.e19
https://doi.org/10.1016/j.cell.2018.05.013
pmid: 29856956
|
28 |
O Humbert, GS Laszlo, S Sichel, C Ironside, KG Haworth, OM Bates, ME Beddoe, RR Carrillo, HP Kiem, RB Walter. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia 2019; 33(3): 762–808
https://doi.org/10.1038/s41375-018-0277-8
pmid: 30291334
|
29 |
F Borot, H Wang, Y Ma, T Jafarov, A Raza, AM Ali, S Mukherjee. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci USA 2019; 116(24): 11978–11987
https://doi.org/10.1073/pnas.1819992116
pmid: 31138698
|
30 |
U Testa, R Riccioni, D Diverio, A Rossini, F Lo Coco, C Peschle. Interleukin-3 receptor in acute leukemia. Leukemia 2004; 18(2): 219–226
https://doi.org/10.1038/sj.leu.2403224
pmid: 14671644
|
31 |
L Jin, EM Lee, HS Ramshaw, SJ Busfield, AG Peoppl, L Wilkinson, MA Guthridge, D Thomas, EF Barry, A Boyd, DP Gearing, G Vairo, AF Lopez, JE Dick, RB Lock. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009; 5(1): 31–42
https://doi.org/10.1016/j.stem.2009.04.018
pmid: 19570512
|
32 |
X Du, M Ho, I Pastan. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30(6): 607–613
https://doi.org/10.1097/CJI.0b013e318053ed8e
pmid: 17667524
|
33 |
A Mardiros, C Dos Santos, T McDonald, CE Brown, X Wang, LE Budde, L Hoffman, B Aguilar, WC Chang, W Bretzlaff, B Chang, M Jonnalagadda, R Starr, JR Ostberg, MC Jensen, R Bhatia, SJ Forman. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013; 122(18): 3138–3148
https://doi.org/10.1182/blood-2012-12-474056
pmid: 24030378
|
34 |
S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, G Danet-Desnoyers, J Scholler, SA Grupp, CH June, M Kalos. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014; 123(15): 2343–2354
https://doi.org/10.1182/blood-2013-09-529537
pmid: 24596416
|
35 |
M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, J Perazzelli, M Klichinsky, V Aikawa, F Nazimuddin, M Kozlowski, J Scholler, SF Lacey, JJ Melenhorst, JJ Morrissette, DA Christian, CA Hunter, M Kalos, DL Porter, CH June, SA Grupp, S Gill. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 2016; 126(10): 3814–3826
https://doi.org/10.1172/JCI87366
pmid: 27571406
|
36 |
V Rebmann, P Schütt, D Brandhorst, B Opalka, T Moritz, MR Nowrousian, H Grosse-Wilde. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 2007; 123(1): 114–120
https://doi.org/10.1016/j.clim.2006.11.007
pmid: 17218152
|
37 |
DC Taussig, DJ Pearce, C Simpson, AZ Rohatiner, TA Lister, G Kelly, JL Luongo, GA Danet-Desnoyers, D Bonnet. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106(13): 4086–4092
https://doi.org/10.1182/blood-2005-03-1072
pmid: 16131573
|
38 |
X Wang, WC Chang, CW Wong, D Colcher, M Sherman, JR Ostberg, SJ Forman, SR Riddell, MC Jensen. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118(5): 1255–1263
https://doi.org/10.1182/blood-2011-02-337360
pmid: 21653320
|
39 |
KC Straathof, MA Pulè, P Yotnda, G Dotti, EF Vanin, MK Brenner, HE Heslop, DM Spencer, CM Rooney. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105(11): 4247–4254
https://doi.org/10.1182/blood-2004-11-4564
pmid: 15728125
|
40 |
P Spear, MR Wu, ML Sentman, CL Sentman. NKG2D ligands as therapeutic targets. Cancer Immun 2013; 13(8): 8
pmid: 23833565
|
41 |
J Hilpert, L Grosse-Hovest, F Grünebach, C Buechele, T Nuebling, T Raum, A Steinle, HR Salih. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189(3): 1360–1371
https://doi.org/10.4049/jimmunol.1200796
pmid: 22730533
|
42 |
SH Baumeister, J Murad, L Werner, H Daley, H Trebeden-Negre, JK Gicobi, A Schmucker, J Reder, CL Sentman, DE Gilham, FF Lehmann, I Galinsky, H DiPietro, K Cummings, NC Munshi, RM Stone, DS Neuberg, R Soiffer, G Dranoff, J Ritz, S Nikiforow. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res 2019; 7(1): 100–112
https://doi.org/10.1158/2326-6066.CIR-18-0307
pmid: 30396908
|
43 |
J Sakamoto, K Furukawa, C Cordon-Cardo, BW Yin, WJ Rettig, HF Oettgen, LJ Old, KO Lloyd. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 1986; 46(3): 1553–1561
pmid: 3510728
|
44 |
JA Westwood, WK Murray, M Trivett, NM Haynes, B Solomon, L Mileshkin, D Ball, M Michael, A Burman, P Mayura-Guru, JA Trapani, S Peinert, D Hönemann, H Miles Prince, AM Scott, MJ Smyth, PK Darcy, MH Kershaw. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J Immunother 2009; 32(3): 292–301
https://doi.org/10.1097/CJI.0b013e31819b7c8e
pmid: 19242371
|
45 |
S Peinert, HM Prince, PM Guru, MH Kershaw, MJ Smyth, JA Trapani, P Gambell, S Harrison, AM Scott, FE Smyth, PK Darcy, K Tainton, P Neeson, DS Ritchie, D Hönemann. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 2010; 17(5): 678–686
https://doi.org/10.1038/gt.2010.21
pmid: 20200563
|
46 |
G Ma, Y Wang, T Ahmed, AL Zaslav, L Hogan, C Avila, M Wada, H Salman. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep 2018; 9(42–44): 42–44
https://doi.org/10.1016/j.lrr.2018.03.002
pmid: 29892548
|
47 |
DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, CD Bloomfield, M Cazzola, JW Vardiman. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391–2405
https://doi.org/10.1182/blood-2016-03-643544
pmid: 27069254
|
48 |
H Jetani, I Garcia-Cadenas, T Nerreter, S Thomas, J Rydzek, JB Meijide, H Bonig, W Herr, J Sierra, H Einsele, M Hudecek. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 2018; 32(5): 1168–1179
https://doi.org/10.1038/s41375-018-0009-0
pmid: 29472720
|
49 |
CD Chien, C Sauter, K Ishii, SM Nguyen, F Shen, SK Tasian, W Chen, DS Dimitrov, TJ Fry. Preclinical development of flt3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Blood 2016; 128(22): 1072
https://doi.org/10.1182/blood.V128.22.1072.1072
|
50 |
Y Wang, Y Xu, S Li, J Liu, Y Xing, H Xing, Z Tian, K Tang, Q Rao, M Wang, J Wang. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol 2018; 11(1): 60
https://doi.org/10.1186/s13045-018-0603-7
pmid: 29716633
|
51 |
D Campana, JJ van Dongen, A Mehta, E Coustan-Smith, IL Wolvers-Tettero, K Ganeshaguru, G Janossy. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood 1991; 77(7): 1546–1554
https://doi.org/10.1182/blood.V77.7.1546.1546
pmid: 1826223
|
52 |
D Campana, FG Behm. Immunophenotyping of leukemia. J Immunol Methods 2000; 243(1-2): 59–75
https://doi.org/10.1016/S0022-1759(00)00228-3
pmid: 10986407
|
53 |
N Tiftik, Z Bolaman, S Batun, O Ayyildiz, A Isikdogan, G Kadikoylu, E Muftuoglu. The importance of CD7 and CD56 antigens in acute leukaemias. Int J Clin Pract 2004; 58(2): 149–152
https://doi.org/10.1111/j.1368-5031.2004.0018.x
pmid: 15055863
|
54 |
H Miwa, K Nakase, K Kita. Biological characteristics of CD7+ acute leukemia. Leuk Lymphoma 1996; 21(3-4): 239–244
pmid: 8726405
|
55 |
D Gomes-Silva, E Atilla, PA Atilla, F Mo, H Tashiro, M Srinivasan, P Lulla, RH Rouce, JMS Cabral, CA Ramos, MK Brenner, M Mamonkin. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther 2019; 27(1): 272–280
https://doi.org/DOI: 10.1016/j.ymthe.2018.10.001
pmid: 30391141
|
56 |
AB Bakker, S van den Oudenrijn, AQ Bakker, N Feller, M van Meijer, JA Bia, MA Jongeneelen, TJ Visser, N Bijl, CA Geuijen, WE Marissen, K Radosevic, M Throsby, GJ Schuurhuis, GJ Ossenkoppele, J de Kruif, J Goudsmit, AM Kruisbeek. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64(22): 8443–8450
https://doi.org/10.1158/0008-5472.CAN-04-1659
pmid: 15548716
|
57 |
J Wang, S Chen, W Xiao, W Li, L Wang, S Yang, W Wang, L Xu, S Liao, W Liu, Y Wang, N Liu, J Zhang, X Xia, T Kang, G Chen, X Cai, H Yang, X Zhang, Y Lu, P Zhou. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 2018; 11(1): 7
https://doi.org/10.1186/s13045-017-0553-5
pmid: 29316944
|
58 |
E Laborda, M Mazagova, S Shao, X Wang, H Quirino, AK Woods, EN Hampton, DT Rodgers, CH Kim, PG Schultz, TS Young. Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci 2017; 18(11): E2259
https://doi.org/10.3390/ijms18112259
pmid: 29077054
|
59 |
SS Kenderian, TM Habermann, WR Macon, KM Ristow, SM Ansell, JP Colgan, PB Johnston, DJ Inwards, SN Markovic, IN Micallef, CA Thompson, LF Porrata, JA Martenson, TE Witzig, GS Nowakowski. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 2016; 127(16): 1960–1966
https://doi.org/10.1182/blood-2015-08-665505
pmid: 26837698
|
60 |
H Tashiro, T Sauer, T Shum, K Parikh, M Mamonkin, B Omer, RH Rouce, P Lulla, CM Rooney, S Gottschalk, MK Brenner. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther 2017; 25(9): 2202–2213
https://doi.org/DOI: 10.1016/j.ymthe.2017.05.024
pmid: 28676343
|
61 |
S Legras, U Günthert, R Stauder, F Curt, S Oliferenko, HC Kluin-Nelemans, JP Marie, S Proctor, C Jasmin, F Smadja-Joffe. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998; 91(9): 3401–3413
https://doi.org/10.1182/blood.V91.9.3401
pmid: 9558399
|
62 |
M Casucci, B Nicolis di Robilant, L Falcone, B Camisa, M Norelli, P Genovese, B Gentner, F Gullotta, M Ponzoni, M Bernardi, M Marcatti, A Saudemont, C Bordignon, B Savoldo, F Ciceri, L Naldini, G Dotti, C Bonini, A Bondanza. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 2013; 122(20): 3461–3472
https://doi.org/10.1182/blood-2013-04-493361
pmid: 24016461
|
63 |
JF Ross, H Wang, FG Behm, P Mathew, M Wu, R Booth, M Ratnam. Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999; 85(2): 348–357
https://doi.org/10.1002/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4
pmid: 10023702
|
64 |
XQ Pan, X Zheng, G Shi, H Wang, M Ratnam, RJ Lee. Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002; 100(2): 594–602
https://doi.org/10.1182/blood.V100.2.594
pmid: 12091353
|
65 |
RC Lynn, M Poussin, A Kalota, Y Feng, PS Low, DS Dimitrov, DJ Powell Jr. Targeting of folate receptor b on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood 2015; 125(22): 3466–3476
https://doi.org/10.1182/blood-2014-11-612721
pmid: 25887778
|
66 |
RC Lynn, Y Feng, K Schutsky, M Poussin, A Kalota, DS Dimitrov, DJ Powell Jr. High-affinity FRb-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 2016; 30(6): 1355–1364
https://doi.org/10.1038/leu.2016.35
pmid: 26898190
|
67 |
H Jiang, C Li, P Yin, T Guo, L Liu, L Xia, Y Wu, F Zhou, L Ai, W Shi, X Lu, H Wang, L Tang, Q Wei, J Deng, R Jin, W Xiong, J Dong, H Mei, Y Hu. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol 2019; 94(10): 1113–1122
https://doi.org/10.1002/ajh.25582
pmid: 31321805
|
68 |
JH Park, I Rivière, M Gonen, X Wang, B Sénéchal, KJ Curran, C Sauter, Y Wang, B Santomasso, E Mead, M Roshal, P Maslak, M Davila, RJ Brentjens, M Sadelain. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018; 378(5): 449–459
https://doi.org/10.1056/NEJMoa1709919
pmid: 29385376
|
69 |
YM Zhu, Z Wu, YP Tan, YY Du, Z Liu, RM Ou, S Liu, CF Pu, J Jiang, JP Wang, L Xiao, Q Zhang. Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: two case reports. Medicine (Baltimore) 2016; 95(51): e5676
https://doi.org/10.1097/MD.0000000000005676
pmid: 28002337
|
70 |
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, HE Stefanski, GD Myers, M Qayed, B De Moerloose, H Hiramatsu, K Schlis, KL Davis, PL Martin, ER Nemecek, GA Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, M Leung, KT Mueller, Y Zhang, K Sen, D Lebwohl, MA Pulsipher, SA Grupp. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378(5): 439–448
https://doi.org/10.1056/NEJMoa1709866
pmid: 29385370
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|